Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 797-805

  Jensen, Berit Packert ^a   Chin, Paul Ken Leong ^a   Roberts, Rebecca Lee ^a,b   Begg, Evan James ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

(R) warfarin; (S) warfarin; Age; Clearance; Free; Protein binding

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; EX VIVO STUDY; FEMALE; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PROTEINS; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, LIQUID; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TIME FACTORS; WARFARIN; YOUNG ADULT;

EID: 84867359146     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04259.x     Document Type: Article

References (24)

1. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84.
2. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008; 47: 297-321.
3. Dollery C. Therapeutic Drugs, 2nd edn. Edinburgh: Churchill Livingstone, 1999.
4. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 1979; 8: 243-7.
5. Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13: 213-27.
6. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40: 203-7.
7. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
8. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-12.
9. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
10. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.
11. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20.
12. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37: 563-9.
13. Hotraphinyo K, Triggs EJ, Maybloom B, Maclaine-Cross A. Warfarin sodium: steady-state plasma levels and patient age. Clin Exp Pharmacol Physiol 1978; 5: 143-9.
14. Hayes MJ, Langman MJ, Short AH. Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins. Br J Clin Pharmacol 1975; 2: 69-72.
15. Abel J, Roth E, Sellers E, Ray A. Drug-plasma protein binding in Kutchin Athapaskan indians. Clin Pharmacol Ther 1982; 32: 436-41.
16. Chin PKL, Jensen BP, Larsen HS, Begg EJ. Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects. Br J Clin Pharmacol 2011; 72: 985-9.
17. Jensen B, Chin P, Begg E. Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS. Anal Bioanal Chem 2011; 401: 2187-93.
18. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S, Kusek JW, Van Lente F, for the Chronic Kidney Disease Epidemiology, Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Inter Med 2006; 145: 247-54.
20. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-91.
21. Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81: 529-38.
22. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727-34.
23. Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2011; 73: 66-76.
24. Richieri GV, Kleinfeld AM. Unbound free fatty acid levels in human serum. J Lipid Res 1995; 36: 229-40.